Managing bone health in women with breast cancer under adjuvant treatment with aromatase inhibitors: pretreatment bone mineral density is important.
Markopoulos
Christos
C
D000077384:Anastrozole; D047072:Aromatase Inhibitors / Q000627:therapeutic use; D015519:Bone Density / Q000187:drug effects*; D050071:Bone Density Conservation Agents / Q000627:therapeutic use; D001851:Bone Diseases, Metabolic / Q000517:prevention & control; D001943:Breast Neoplasms / Q000188:drug therapy*; D017024:Chemotherapy, Adjuvant; D004164:Diphosphonates / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D009570:Nitriles / Q000627:therapeutic use*; D010024:Osteoporosis / Q000517:prevention & control; D014230:Triazoles / Q000627:therapeutic use*
D047072:Aromatase Inhibitors; D050071:Bone Density Conservation Agents; D004164:Diphosphonates; D009570:Nitriles; D014230:Triazoles; D000077384:Anastrozole